Erlonat 100mg

Erlonat 100 mg is a prescription treatment for patients with advanced or metastatic non-small cell lung cancer (NSCLC) with activating EGFR mutations. It is effective in treating patients with locally advanced or metastatic NSCLC who have previously received chemotherapy. Erlonat, in combination with gemcitabine, is used to treat patients with locally advanced, or metastatic cancer. The medicines contain the active substance Erlotinib, which treats cancer by preventing the activity of a protein called epidermal growth factor receptor (EGFR), a protein involved in the growth and spread of cancer cells.